Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.
Kanglong Huacheng (03759) announced that in order to further enhance the production capacity of new drug commercialization and CDMO R&D production services, continuously strengthen the integrated service capabilities of new molecular type projects, consolidate the foundation of core business, and comprehensively enhance comprehensive competitiveness and industry market position, the company plans to invest approximately RMB 2 billion to establish a new drug commercialization production and CDMO R&D production service base in Qiantang District, Hangzhou. On May 27, 2026, the company signed an "Investment Agreement" with Hangzhou Qiantang District Investment Promotion Service Center regarding the Hangzhou project.
Pharmaron Beijing (03759) has announced plans to invest approximately 2 billion yuan in the construction of a new drug commercial production and CDMO R&D production base in Qiantang District, Hangzhou (Hangzhou project) to further enhance the capacity for commercial production of new drugs and CDMO R&D production services, continuously strengthen the integrated service capabilities for new molecular types projects, solidify the foundation of core business, and comprehensively improve overall competitiveness and market position in the industry. On May 27, 2026, the company signed an "Investment Agreement" with the Hangzhou Qiantang District Investment Promotion Service Center regarding the Hangzhou project.
According to relevant laws, regulations, and the company's articles of association, this matter falls within the authorization of the board of directors and does not require approval from the shareholders' meeting. The board of directors approved the investment in the construction of the new drug commercial production and CDMO R&D production base and the investment agreement on May 26, 2026.
Related Articles
GT GOLD (08299) completed the placement of 398 million shares, raising approximately 1.653 billion Hong Kong dollars.
Future Data (08229): Leung Ho Ming retires as an independent non-executive director.
Shanghai Stock Exchange: WELLCELL H-OLD (02940) will be removed from the list of Hong Kong stocks eligible for trading under the Shanghai-Hong Kong Stock Connect.
GT GOLD (08299) completed the placement of 398 million shares, raising approximately 1.653 billion Hong Kong dollars.
Future Data (08229): Leung Ho Ming retires as an independent non-executive director.
Shanghai Stock Exchange: WELLCELL H-OLD (02940) will be removed from the list of Hong Kong stocks eligible for trading under the Shanghai-Hong Kong Stock Connect.
